Tardive Dyskinesia: Minimizing Risk and Improving Outcomes in Schizophrenia and Other Disorders

Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.

Phase 3 trials found oveporexton improved wakefulness, sleepiness, and cataplexy in narcolepsy type 1, with insomnia and urinary frequency common.

The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.

A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.

A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.

Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.

Symptom-tracking tools may improve awareness and patient-clinician communication but can also add stress.

Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.